Stem Cell Therapy in Muscular Dystrophy

Neurogen Brain and Spine Institute

Status and phase: Withdrawn; Phase 1

Conditions: Muscular Dystrophy

Treatments: Biological: Stem Cell

Study type: Interventional

Funder types: Other

Identifiers

NCT02241928

NGBSI-14

Details and patient eligibility

About

The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

Sex: All

Ages: 6 months to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age group of 6 months and above
• muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion criteria

• presence of respiratory distress
• presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
• malignancies
• acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
• pregnancy or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Stem Cell

Experimental group

Description:

Bone marrow mononuclear cell transplantation

Treatment:

Biological: Stem Cell